Received Apr 13, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
patient got a first shot, then two and a half years later received the second shot; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix. On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: patient got a first shot, then two and a half years later received the second shot). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 01-APR-2026 The reporter wanted to know if the patient eligible for a booster dose, since the patient would be coming tomorrow to get another shot, the reporter wanted to have the information to advise the patient not to come tomorrow if it was not necessary. The batch number was not provided upon follow- up with the reporter.